BioCryst Pharmaceuticals BCRX Business Segments — Net (loss) income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's business segments — net (loss) income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's business segments — net (loss) income?
- BioCryst Pharmaceuticals (BCRX) reported business segments — net (loss) income of -$721.81M in Q1 2026.
- How has BioCryst Pharmaceuticals's business segments — net (loss) income changed year-over-year?
- BioCryst Pharmaceuticals's business segments — net (loss) income decreased by 2255762.5% year-over-year, from $32K to -$721.81M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — net (loss) income?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's business segments — net (loss) income has grown at a 2.2% compound annual growth rate (CAGR), from -$247.12M to $263.86M.
- What does business segments — net (loss) income mean?
- Measures the final profit or loss generated by the business segment after accounting for all revenues, operating expenses, interest, and taxes. It serves as the primary indicator of the segment's overall financial health and contribution to the company's total earnings.